英国学术临床试验监测实践调查
监测实践差异大,多数用中心监测引导现场访视,79%视优化中心监测为最紧迫问题。亟需基于证据的监管共识指南。
要点
- 97%(36/37)的CTU使用中心监测流程引导、靶向或补充现场访视。
- 91%(31/34)的CTU使用触发指标决定是否进行现场监测访视。
- 79%(27/34)的CTU将优化中心监测列为最紧迫关注点。
核心结论
- 英国学术临床试验单位的III期随机CTIMP试验监测实践差异较大,亟需制定基于证据且监管机构认可的中心与现场监测最佳实践指南及工具。
主要发现
- 43/50(86%)的CTU回复,其中38个开展III期随机CTIMP试验,34个完成调查。
- 36/37(97%)的CTU使用中心监测流程引导、靶向或补充现场访视。
- 19/36(53%)的CTU在中心监测时不使用自动化监测报告,所有单位均用试验团队知识决定是否需现场访视。
- 31/34(91%)的CTU使用触发指标决定是否进行现场监测访视。
- 27/34(79%)的CTU将优化中心监测列为最紧迫关注点。
临床怎么用
- 学术CTU可参考调查中中心监测引导现场访视、触发指标决策和混合源数据核查与流程检查的现行做法。
局限性
- 调查仅覆盖英国UKCRC注册CTU,回复率为86%,结果可能不适用于其他国家或非注册单位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) encouraging the use of risk-based monitoring for trials in 2013, there remains a lack of evidence-based guidelines on how to monitor. We surveyed the academic United Kingdom Clinical Research Collaboration (UKCRC) registered clinical trials units (CTUs) to find out their policy on monitoring of phase III randomised clinical trials of an investigational medicinal product (CTIMPs). METHODS: An online survey of monitoring policy with sections on the CTU, central monitoring and on-site monitoring was sent to all 50 UKCRC registered CTUs in November 2018. Descriptive data analysis and tabulations are reported using the total number answering each question. RESULTS: A total of 43/50 (86%) of CTUs responded with 38 conducting phase III randomised CTIMP trials. Of these 38 CTUs, 34 finished the survey. Most CTUs (36/37, 97%) use a central monitoring process to guide, target or supplement site visits. More than half (19/36, 53%) of CTUs do not use an automated monitoring report when centrally monitoring trials and all units use trial team knowledge to make a final decision on whether an on-site visit is required. A total of 31/34 (91%) CTUs used triggers to decide whether or not to conduct an on-site monitoring visit. On-site, a mixture of source data verification and checking of processes was carried out. The CTUs overwhelmingly (27/34, 79%) selected optimising central monitoring as their most pressing concern. CONCLUSION: The survey showed a wide variation in phase III randomised CTIMP trial monitoring practices by academic clinical trials units within a single research-active country. We urgently need to develop evidence-based regulator-agreed guidance for CTUs on best practice for both central and on-site monitoring and to develop tools for all CTUs to use.
引用
- Love SB, Yorke-Edwards V, Lensen S, et al. Monitoring in practice - How are UK academic clinical trials monitored? A survey. Trials. 2020. PMID: 31918743. doi:10.1186/s13063-019-3976-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。